Addressing the Social and Economic Burden of Disease in Turkey 2012-2013

7/29/2019 Addressing the Social and Economic Burden of Disease in Turkey 2012-2013

1/16

Addressing theSocial and

Economic Burdenof Disease in Turkey

2012-2013

Summary Report of a Multi-Sector Outreach Project


2/16

Key Project Elements

Stakeholders: Identify health-focused civil societyorganizations patient & business

Analytics: Research paper on the burden of chronicdisease in Turkey by respected Turkish and Internationalacademic experts

Public Policy: Engage the Turkish Ministry of Health (healthPromotion and Prevention Branch)


3/16

Stakeholder Mapping in Turkey

Objective:

to identify stakeholders with an interest in social andeconomic burden of chronic disease

Results:

79 organizations - including patients rights groups,foundations, economists and academics and health careprovider groups with mandate related to access to

healthcare

61 groups and individuals were selected for follow-upquestionnaires and interviews


4/16

Stakeholder Audit

Interviews determined:

The therapeutic area of interest A key contact and leadership Corporate structure and governance Source of funding Visibility and/or level of activity Purpose, objective and primary activities


5/16

Stakeholder Engagement

Result

40-45 organizations invited to a workshop in Oct. 2012 todiscuss burden of chronic disease in Turkey.

Workshop participants: Health Development Directorate of the Turkish Ministry of

Health, Prof Mehtap Tatar Haceteppe University and study co-author, patient advocacy leader from civil society

organization in India, a representative of the Partnership toFight Chronic Disease, a U.S.-based NGO.

A follow up workshop Sept. 2013 in Istanbul


6/16

Analytics: Transforming Health In Turkey

Co-authors

Professor David Taylor and Dr. Sarah Carter , UCL School ofPharmacy

Professor Dr. Mehtap Tatar, Hacettepe University Dr. Panos Kanavos and Dr. Federico Grimaccia and Dr.

David Tordrup, LSE Health

Paper was shared with key officials from Turkeys Ministry ofHealth prior to release

Turkey MoH participated in release of the paper at a pressconference in Ankara

Transforming Health in Turkey: 21st Century Opportunitieshttp://www.fightchronicdisease.org/media-center/resources/transforming-health-turkey-21st-century-opportunities


7/16

Key Points Identified

Our report places recent health advances in Turkey incontext of global health improvement in the 20th century

Recognizes opportunities for further improvement in the21st century.

Meant to share information, promote mutualunderstanding, not to impose external agenda on Turkishpolicy makers.



8/16

Key Points

Health Improvement in Turkey

Since 1970 life expectancy at birth has risen by 25 yearsand the infant death rate has fallen from about 150 tounder 10 per 1000 live births

However, rising rates of non-communicable disease andLTD causing welfare losses that cost more than currentspending all all forms of health care

Type 2 diabetes has doubled in little more than adecade, above the rate recorded in the US

High vascular disease burdens, relatively high incidenceof COPD and similar conditions



9/16

NCDs Cost Turkey in Excess of US $80b

6.5 million DALYs a year (disability adjusted life years)


10/16

The Importance of Positive Active

Ageing

Policy makers across the world can help to facilitatepositive active ageing through progressive public policy

Prevention and treatment of chronic disease improveshealth at every stage in life, reduces the costs, andopens the way to increased economic productivity

Turkey will benefit more from a healthy and active olderpopulation than a young population with sub-optimal

treatment of long term illness



11/16

Economic Losses could be Reduced

if Risk Factors were Eliminated


12/16

Public Health, National Wealth and

the Role of Pharmaceutical Care

Continue to support economic growth by: Minimizing maternal mortality Promoting the rational use of medicines, smoking cessation,

and exercise amongst both men and women

Use medicines to reduce blood pressure/ cholesterol andto prevent disabilities caused by diabetes or asthma toincrease value in social circumstances

As people age and transition socially they demandenhanced health/social services, and treatments for laterlife conditions such as cancers



13/16

Rational Use of Rx


14/16

Turkeys Opportunities

Increase health investment from the current level of 6 percent of GDP to the OECD average of 9 per cent

Increase the use of pharmaceuticals as a cost effectivehealth care option

Increase the number of primary care professionals Promote innovative pharmacy based services



15/16

Fighting Chronic Disease

Patient-Focused Policies and Practices

Advance sustainable-next generation chronic diseaseprevention, early intervention, and management modelsthroughout the health care system and public health

infrastructure

Promote healthy lifestyles and disease prevention andmanagement in every community

Encourage and reward continuous advances in clinicalpractice and research that improve the quality of care forthose with prevalent and costly chronic diseases

Partnership to Fight Chronic Disease http://www.fightchronicdisease.org/about/


16/16

Fighting Chronic Disease

Patient-Focused Policies and Practices

Accelerate improvements in the quality and availability ofhealth information technology (HIT) throughout the healthcare system

Reduce health disparities by focusing on barriers to goodhealth

Partnership to Fight Chronic Disease http://www.fightchronicdisease.org/about/

Documents

Addressing the Social and Economic Burden of Disease in Turkey 2012-2013